ARCA biopharma Announces C. Jeff Dekker to be Appointed Main Economical Officer
Get quick alerts when news breaks on your shares. Claim your 1-week cost-free demo to StreetInsider Premium here.
WESTMINSTER, Colo., May well 03, 2021 (Globe NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company implementing a precision drugs technique to developing genetically targeted therapies for cardiovascular health conditions, these days announced C. Jeff Dekker as its Main Monetary Officer, powerful May possibly 10, 2021, following Brian Selby’s planned departure after 14 many years of service with the Enterprise.
Dr. Michael Bristow, ARCA’s President and Chief Govt Officer commented: “We are delighted to welcome Jeff to ARCA as our Main Economic Officer. Jeff brings in excess of 25 years of biotech industry and finance working experience. I am self-assured he will be a robust CFO for ARCA. We think his broad practical experience and capabilities in all elements of finance, his basic understanding of our organization and the field, and his strong leadership, uniquely help Jeff to help us carry on to travel our clinical enhancement and company strategies.”
Dr. Bristow commented further, “Over his 14 years of support, Brian has created invaluable contributions to ARCA. His partnership and direction directing our money and accounting firm presented a steady foundation to assistance progress our clinical growth applications. Although we will skip his leadership, collaboration and insight, we wish him perfectly in his foreseeable future endeavors.”
Prior to joining ARCA, Mr. Dekker served in a number of roles of raising obligation at GlobeImmune, Inc. from 2006 to 2021, which include President, Vice President of Finance, and Senior Director, Finance and Controller. Ahead of becoming a member of GlobeImmune, Mr. Dekker held management positions in finance and accounting at personal software program organizations considering that 1993, which includes posts ranging from Corporate Controller to Vice President at Webroot Application Inc., Requisite Technology Inc. and NxTrend Technology Inc. Previously in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He gained a B.S. in accounting from Utah Condition University and is a qualified public accountant.
About ARCA biopharmaARCA biopharma is focused to establishing genetically focused therapies for cardiovascular illnesses by means of a precision medicine technique to drug advancement. ARCA is establishing rNAPc2 as a probable cure for disorders triggered by RNA viruses, to begin with concentrating on COVID-19. The U.S. Food and drug administration has granted Quick Observe designation to the rNAPc2 improvement application, at this time in Section 2 medical testing. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically one of a kind beta-blocker and moderate vasodilator, as a possible remedy for atrial fibrillation in coronary heart failure individuals. ARCA has identified frequent genetic versions that it thinks predict specific client response to Gencaro, giving it the possible to be the initial genetically focused AF prevention cure. The U.S. Food and drug administration has granted the Gencaro enhancement plan Rapid Observe designation and a Particular Protocol Evaluation (SPA) arrangement. For much more information and facts, you should visit www.arcabio.com or comply with the Company on LinkedIn.
Risk-free Harbor StatementThis push release is made up of “forward-seeking statements” for uses of the protected harbor offered by the Non-public Securities Litigation Reform Act of 1995. These statements consist of, but are not constrained to, statements with regards to the opportunity foreseeable future development programs for rNAPc2 and Gencaro, the anticipated functions and traits of rNAPc2 and Gencaro, such as the opportunity for genetic versions to predict specific client response to Gencaro, Gencaro’s probable to treat atrial fibrillation, rNAPc2’s opportunity to address COVID-19, and the opportunity for Gencaro to be the very first genetically focused AF prevention therapy. These types of statements are based mostly on management’s present anticipations and contain hazards and uncertainties. Real success and functionality could differ materially from people projected in the ahead-looking statements as a outcome of a lot of aspects, together with, without limitation, the dangers and uncertainties associated with: ARCA’s fiscal means and whether or not they will be enough to meet its business objectives and operational demands ARCA may not be in a position to increase enough funds on appropriate phrases, or at all, to continue enhancement of rNAPc2 or Gencaro or to if not go on operations in the long term effects of earlier scientific trials may not be verified in long run trials the security and sector exclusivity supplied by ARCA’s mental home threats associated to the drug discovery and the regulatory approval method and, the affect of competitive merchandise and technological improvements. These and other components are identified and described in additional detail in ARCA’s filings with the Securities and Exchange Commission, like devoid of limitation ARCA’s annual report on Form 10-K for the year finished December 31, 2020, and subsequent filings. ARCA disclaims any intent or obligation to update these ahead-looking statements.
Investor & Media Call:Derek Cole720.940.2163[email protected]
A photograph accompanying this announcement is offered at https://www.globenewswire.com/NewsRoom/AttachmentNg/af496e97-20da-420a-bf93-e51b3a3ed740
Dr. Bristow
Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc.
Source: ARCA biopharma, Inc.